Filing Flows › Arcutis Biotherapeutics (ARQT) › Who owns the stock
Who owns Arcutis Biotherapeutics (ARQT) stock
274 funds reported Arcutis Biotherapeutics (ARQT) shares in their latest 13F filings, worth $3.6B in all. The largest holder is Suvretta Capital Management, LLC ($326M). Last quarter 123 funds added to their stakes and 127 cut them. Members of Congress and other officials disclosed 3 trades (2 buys, 1 sales).
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12,437,000 | $326M | increase | 2026-06-30 |
| BlackRock | 10,545,466 | $277M | increase | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 9,874,511 | $259M | unchanged | 2026-06-30 |
| Rubric Capital Management LP | 8,271,577 | $217M | unchanged | 2026-06-30 |
| Vanguard Group | 7,253,936 | $211M | increase | 2025-12-31 |
| Polar Capital Holdings | 6,606,945 | $173M | increase | 2026-06-30 |
| State Street | 5,822,840 | $153M | decrease | 2026-06-30 |
| Vanguard Capital Management LLC | 4,988,756 | $131M | increase | 2026-06-30 |
| Morgan Stanley | 4,451,014 | $117M | increase | 2026-06-30 |
| Jennison Associates LLC | 4,219,058 | $111M | decrease | 2026-06-30 |
| D. E. Shaw | 3,949,609 | $104M | increase | 2026-06-30 |
| UBS Group AG | 3,333,015 | $87.4M | increase | 2026-06-30 |
| Bank of America | 2,987,431 | $78.3M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 2,982,446 | $78.2M | decrease | 2026-06-30 |
| Vanguard Portfolio Management LLC | 2,429,005 | $63.7M | increase | 2026-06-30 |
Trades by Congress and other officials
| Date | Who | Trade | Amount |
|---|---|---|---|
| 2026-05-29 | Gilbert Cisneros | purchase | $1K–$15K |
| 2026-03-03 | Gilbert Cisneros | purchase | $1K–$15K |
| 2025-12-11 | Gilbert Cisneros | partial sale | $1K–$15K |
Arcutis Biotherapeutics' latest quarter
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ARQT stock?
By the latest 13F filings: Suvretta Capital Management, LLC ($326M); BlackRock ($277M); Frazier Life Sciences Management, L.P. ($259M); Rubric Capital Management LP ($217M); Vanguard Group ($211M).
Has Congress traded ARQT stock?
Officials disclosed 3 trades on file: 2 buys and 1 sales. The latest: Gilbert Cisneros, purchase on 2026-05-29.
What is the short interest in ARQT?
20,485,453 shares were sold short at the 2026-10-15 settlement, -5.55% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.